KRRO a biotech company with earnings coming LONG
KRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods .
A recent analyst gave it an upside to 100 which is very favorable given its product line and track
record with an all-time high of about $250 ( which is about 450% over current valuation)
On the one-hour time frame, it has had a great week and is breaking out over its moving
averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade
in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic
reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and
$75.00 for most of the position in consideration of the analyst report.
A recent analyst gave it an upside to 100 which is very favorable given its product line and track
record with an all-time high of about $250 ( which is about 450% over current valuation)
On the one-hour time frame, it has had a great week and is breaking out over its moving
averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade
in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic
reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and
$75.00 for most of the position in consideration of the analyst report.
Trade active
Price is currently 15-17% below a significant level of resistance which could potentially be broken.Trade active
If KRRO can break through 54 then I see room to 59 at the top of the high volume area of the volume profile.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.